Drugs.com - New Drug Approvals

FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved...

Feb 12, 2025 - 00:36
 0
FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved...
Read More

Tags:

Previous Article

Solutions for Every Hold

Next Article

Simple Congenital Heart Diseases Tied to Higher Epilepsy Risk

Related Posts

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Spravato (esketamine) Approved in the U.S. as the First...

Feb 9, 2025  0

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar t...

Feb 9, 2025  0